Federal Circuit’s en banc MedCo ruling clarifies on-sale bar
In a unanimous en banc decision in The Medicines Company v Hospira, the Federal Circuit addressed and clarified the “on sale” bar, a source of much anxiety for pharmaceutical companies
The Federal Circuit sitting en banc ruled in its The Medicines Company v Hospira opinion that MedCo’s purchase of manufacturer Ben Venue’s services to produce its anticoagulant drug Angiomax, which contains blood thinner bivalirudin, did not trigger the on-sale bar,...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.